” WHO facilitated the accelerated search for safe and effective vaccines, resulting in vaccine development in less than 12 months versus 10+ years.
In July 2015, WHO announced the results of an interim analysis of a Phase III efficacy trial for the Ebola vaccine VSV-EBOV conducted in Guinea. Preliminary results suggest that the vaccine is highly effective. The trial was extended to Sierra Leone.
WHO, the Emerging and Dangerous Pathogens Laboratory Network (EDPLN), and partners have evaluated novel diagnostic assays for the detection of EVD. Six diagnostic assays have been approved for UN procurement.
Clinical trials using convalescent whole blood and convalescent plasma from survivors have been limited to fewer than 100 patients, but have shown that blood and plasma collection can be safe and feasible in the context of an Ebola outbreak. WHO supported strengthening national blood transfusion services for the purpose of safely administering convalescent whole blood and plasma products from Ebola survivors to Ebola patients.
In addition, experts have reviewed and identified a few medicines and drugs – out of hundreds of recommendations – for use in treating Ebola patients or for further clinical studies. These include: ZMapp – a monoclonal antibody cocktail; favipiravir – a small-molecule antiviral; and several small-molecule antivirals with potent anti-Ebola virus activity. All continue to be tested for safety and efficacy.”